Local advocates to mark Oregon Cancer Action Day in Salem
PORTLAND, Ore. (KOIN) – Tuesday, April 1st, marks , a time when Oregonians affected by the deadly disease come together in hopes to inspire change on the legislative level.
Members of the local chapter of the American Cancer Society's Cancer Action Network will be in Salem fighting for solutions to reduce the burden of cancer in our communities.
New bill proposes repealing vote-by-mail in Oregon, public invited to testify
One of the youth leaders of the movement, Lake Oswego High School junior Naomi Robinson, joined us on AM Extra with a look at their Oregon Cancer Action Day agenda.Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
‘Horrifying': PNW senators slam forced removal of Sen. Padilla from DHS press conference
PORTLAND, Ore. (KOIN) — Senators from the Pacific Northwest are reacting Thursday after a U.S. senator was taken to the ground and handcuffed at a press conference held by Homeland Security Secretary Kristi Noem. Senator Alejandro Padilla (D-Calif.) was forcibly removed from the press conference after introducing himself and saying he had questions for Noem amid immigration raids in his state that have led to protests. Videos of the incident shows officers aggressively pushing Padilla out of Noem's press conference and eventually restraining him on the floor outside the room. Oregon joins brief opposing Trump's military deployment to California Sen. Jeff Merkley says what happened is an overstep by the FBI and police, resembling that of a dictatorship. 'It's about not wanting to hear a voice of dissent,' he said. 'Our constitution is based on the freedom of assembly and the freedom of speech and the freedom to petition your government with grievances and that was exactly what he was doing. He has a grievance, he feels it is outrageous — and so do I and I must say, much of the nation — that the president overrode the governor of California and the mayor of L.A. and has poured gasoline on this fire.' When , Sen. Ron Wyden put forth what he believes to be the potential broader significance of this incident. 'It is a horrifying video, truly horrifying,' he said. 'And I'm of the view, Mr. President, why I especially wanted to come to the floor, it is not about it happening to a United States senator. Here is what it's about: If they'll do this to a sitting United States senator in front of a roomful of media, imagine what is being done to powerless people in secret.' Sen. Patty Murray (D-Wash.) said it was the closest she had come to tearing up on the floor in her 32 years in the Senate. 'It is unacceptable that a United States senator in his own home state, elected by millions of people, went to ask a question for his constituents to get an answer and was brutally thrown to the ground and handcuffed,' Murray emphasized. 'That is wrong and I cannot believe that we don't have senators on both sides of the aisle calling this out as outrageous.' Former Washington state worker claims she was ousted over trans athlete vote Senate Republicans were mostly silent on the situation. But Senate Majority Leader John Thune (R-S.D.) said that he would have a response, 'but I want to know the facts, find out exactly what happened.' In a statement, the Department of Homeland Security said Padilla 'chose disrespectful political theater and interrupted a live news conference.' They defended the officers' conduct and claimed erroneously that Padilla did not identify himself and said the Secret Service believed him to be an attacker. The Democrats described Padilla, the son of immigrants from Mexico, as a 'kind and gentle person' and said that disrespect is not a crime in the United States. They also invoked the end of Trump's last presidency, when a mob of his supporters attacked the Capitol and sent them running. The Associated Press contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
15 hours ago
- Yahoo
Oregon joins brief opposing Trump's military deployment to California
PORTLAND, Ore. (KOIN) – Oregon is joining a legal brief with 19 other states opposing President Donald Trump's move to deploy the military in California to assist with immigration raids. Oregon Attorney General Dan Rayfield and the coalition of attorneys general filed the brief Wednesday, calling the president's decision to deploy the military an 'unconstitutional attempt to federalize and deploy California's National Guard.' In the last week, the Trump administration has expanded military deployment to Los Angeles, stating it is willing to send troops to other cities to assist with immigration enforcement and 'controlling disturbances,' the Associated Press reported Thursday, noting about 2,000 National Guard soldiers are in Los Angeles with about 2,000 more expected to join along with 700 Marines. Kotek, Democratic Governors call Trump's use of California's National Guard an 'alarming abuse of power' With their brief, the attorneys general are supporting California Governor Gavin Newsom's request for the court to stop the deployment — calling the move an overreach of presidential power. According to the attorneys general, Trump's order allows the federal government to deploy state National Guard troops without justification, which the attorneys general say sets a precedent that could threaten the balance between civilian authority and military force. 'By calling forth troops when there is no invasion to repel, no rebellion to suppress, and when state and local law enforcement is fully able to execute the laws, the President flouts the vision of our Founders, undermines the rule of law, and sets a chilling precedent that puts the constitutional rights of Americans in every state at risk,' the brief says. How the 'can dam' at Goss Stadium garnered national attention during Corvallis Super Regional The attorneys general note that Trump's order does not limit the deployment to a specific location or purpose; rather, it shows 'broad authority' to activate any state's National Guard for 60 days without cooperation from state leaders. 'Our Guard members aren't tools for political theater – they're trusted partners in our day-to-day public safety,' said Attorney General Rayfield. 'This attempted power grab undermines the states' ability to respond to disasters and protect citizens. It's not just unconstitutional – it's a threat to the systems we rely on.' The attorneys general noted that the order directing 'unchecked federal military deployment' could also suppress First Amendment activity. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Oregon joins the attorneys general representing Arizona, Colorado, Connecticut, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New Mexico, New York, North Carolina, Vermont, Washington and Wisconsin in the brief. Kansas Governor Laura Kelly also joined in support. The brief comes as a judge is set to decide whether to grant Gov. Newsom's request to stop the deployment on Thursday, as reported by the Associated Press. On Wednesday, the Trump administration called the governor's lawsuit a 'crass political stunt endangering American lives.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Health Line
15 hours ago
- Health Line
Are Biomarker Testing and Genetic Testing the Same Thing?
Biomarker testing and genetic testing have different purposes in diagnosing colorectal cancer. The first helps doctors understand cancer's growth and spread, while the second assesses a person's inherited risk. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. It's sometimes referred to as 'colon cancer' or 'rectal cancer,' depending on the area it first develops. According to the American Cancer Society, more than 150,000 new cases of colorectal cancer are expected in 2025. It's one of the top causes of cancer-related death, while the overall risk of developing CRC for people assigned male at birth is about 1 in 24, and 1 in 26 for those assigned female at birth. Despite being one of the most common cancers globally, survival rates for CRC have improved in many parts of the world due to medical advancements in biomarker testing and genetic testing. Both biomarker testing and genetic testing in CRC involve screening for genetic mutations, but these tests have distinct purposes during the diagnosis process. You'll notice that the language used to share stats and other data points is pretty binary, fluctuating between the use of 'male' and 'female' or 'men' and 'women.' Although we typically avoid language like this, specificity is key when reporting on research participants and clinical findings. The studies and surveys referenced in this article didn't report data on or include participants who were transgender, nonbinary, gender nonconforming, genderqueer, agender, or genderless. What is biomarker testing? Biomarker testing in medicine is used to assess, predict, or monitor disease progression. Biomarkers (biological markers) are measurable biological processes, molecules, and cellular changes that provide insight into what's happening in your body at an exact moment. The presence or absence of biomarkers or their changes provides important insight into a developing or progressing medical condition. In CRC, biomarker testing, also called 'tumor testing,' is performed on cancer cells to look for tumor-specific changes. It detects the presence of acquired genetic mutations (somatic mutations), cellular changes, and DNA changes in cancer that could influence its growth and spread. CRC biomarkers can relay information about your overall outlook and whether CRC may be responsive to certain treatments more than others. What is genetic testing? Genetic testing is a specific type of biomarker testing that analyzes your DNA to determine your risk of cancer. In CRC, genetic testing looks for inherited genetic mutations or variants (called germline mutations) associated with an increased risk of CRC. Genetic testing is mainly used as a form of risk assessment. Doctors perform these tests if you have a family history of CRC or meet the criteria for an inherited cancer syndrome. If you've received a diagnosis of CRC and didn't undergo genetic testing first, your doctor may still recommend testing after a diagnosis in certain instances. These include when there's a family history of CRC or if the disease appears to follow a hereditary pattern of development. Types of testing There are several types of tests doctors run when assessing biomarkers and genetic risk in CRC, including: Single gene: This looks for an isolated gene. Panel test: This screens multiple genes at once. Whole-genome sequencing: This assesses all the DNA in a cell. Whole-exome sequencing: This screens only the components in a gene responsible for protein coding. Tumor-mutational burden: This determines the overall number of genetic changes in a tumor's DNA. Common tumor biomarkers Biomarker testing in CRC screens for various measurable tumor indicators, including genetic mutations, protein expression levels, signaling molecules, DNA sequencing patterns, antigens, and more. Common CRC tumor biomarkers your doctor may test for include: MSI-H/dMMR sidedness (which side of the colon the cancer is located on) KRAS NRAS BRAF HER2 EGFR CEA TRK fusions DPD ctDNA PD-L1 pathway WNT pathway RET VEGF CTC MMR deficiency Common genetic tests Genetic testing for CRC typically includes screening for genetic mutations relating to inherited cancer syndromes such as: Lynch syndrome familial adenomatous polyposis (FAP) MUTYH-associated polyposis Peutz-Jeghers syndrome These are inherited conditions that significantly increase your risk of developing CRC. Genes that may be screened in genetic testing for CRC risk include: MLH1 MSH2 MSH3 MSH6 PMS2 APC MUTYH POLE POLD1 NTHL1 GREM1 RNF43 (primarily used in research) RPS20 (primarily used in research) Benefits of testing Genetic testing and biomarker testing in CRC are part of precision medicine and can help improve your cancer outcomes. Genetic testing before a potential cancer diagnosis allows you and your doctor to understand your individual risk for CRC. Knowing your likelihood can help you take preventive steps to lower your overall risk of cancer and can help detect cancer in its earliest, most treatable stages. If you've received a CRC diagnosis, biomarker testing reveals details about the disease that help your doctor treat it with the most effective therapies right from the start. Certain biomarkers, for example, can indicate if CRC will be responsive to immunotherapy or monoclonal antibody therapy. Other biomarkers can help predict treatment response and monitor recurrence. Qualification criteria Anyone with a CRC diagnosis is a candidate for biomarker testing to help direct treatment planning, but not everyone requires genetic testing to determine their inherited risk. Genetic testing is typically recommended when: you have a family history of CRC or a hereditary cancer syndrome in more than one biological relative you received a CRC diagnosis before the age of 50 CRC was diagnosed in a first-degree relative younger than age 50 multiple family members have received a diagnosis of another type of cancer associated with hereditary cancer syndromes (like ovarian or stomach cancer) you've received a diagnosis of two or more primary types of cancer biomarker testing suggests a germline mutation you have a significant number of colorectal polyps How to talk with your doctor Anyone can develop CRC, so the United States Preventive Services Task Force (USPSTF) recommends screening for all adults ages 45 and over. However, you don't have to wait until you are 45 to talk with your doctor about CRC, especially if you have a family history of the condition or inherited cancer syndromes. To help make the most of this conversation with your doctor, consider these tips: Research CRC and learn as much as you can before your appointment. Talk with your parents and biological family members to verify your family medical history. Bring a written list of questions. Have a friend or loved one come with you for support and another perspective. Take notes on what your doctor says to review at home. If you've already had biomarker testing or genetic testing for CRC, questions that may be helpful to ask your doctor include: Which genes and biomarkers were tested for? Did my tests show any biomarkers or inherited mutations? What do the results of my tests mean for my CRC risk or treatment planning? Were all possible biomarkers tested for? If not, why? Will more genetic or biomarker testing be necessary?
